While a multitude of ongoing disease-modifying pharmacotherapies targeting tau in PSP, including genetic, microtubule-stabilizing, anti-phosphorylation and acetylation agents, anti-aggregants, and protein removal. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.